| 中文名称 | 3-[[4-[2-[(3-氯苯基)氨基]-4-嘧啶基]-2-吡啶基]氨基]-1-丙醇 |
| 英文名称 | 3-[[4-[2-[(3-Chlorophenyl)amino]-4-pyrimidinyl]-2-pyridinyl]amino]-1-propanol |
| CAS号 | 164658-13-3 |
| 分子式 | C18H18ClN5O |
| 分子量 | 355.82 |
| EINECS号 | 200-258-5 |
| 熔点 | 144-147℃ |
| 沸点 | 630.6±65.0 °C(Predicted) |
| 密度 | 1.356 |
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 粉末 |
| 酸度系数(pKa) | 14.93±0.10(Predicted) |
| 颜色 | 浅黄至黄色 |
|
CDK1-Cyclin B 26 nM (IC 50 ) |
CDK2/cyclinE 3 nM (IC 50 ) |
cdk2/cyclin A 4 nM (IC 50 ) |
CDK4/cyclin D 216 nM (IC 50 ) |
Cdk5/p25 10 nM (IC 50 ) |
CDK7/cyclin H 200 nM (IC 50 ) |
CDK9/cycT 13 nM (IC 50 ) |
PKC
|
CGP60474 (Compound A) is a potent VEGFR-2 inhibitor, with an IC 50 of 84 nM. CGP60474 is also a PKC inhibitor, with competitive kinetics relative to ATP.
CGP-60474 (10 mg/kg; i.p.) inhibits the IL-6 level and increases the survival rate in the LPS endotoxemia model.
| Animal Model: | C57Bl/6 mice (LPS endotoxemia model) |
| Dosage: | 10 mg/kg |
| Administration: | I.p. |
| Result: | Had a higher survival rate. |
